IQ-AI

IQ-AI is a health imaging and biotechnology company focused on providing clinical software and therapeutic solutions for oncology, particularly neuro-oncology. Its primary subsidiary, Imaging Biometrics, develops advanced medical imaging software that automates the processing of routine MRI and CT scans to improve the diagnosis and monitoring of brain tumors. The company is also advancing a clinical-stage drug candidate, Gallium Maltolate, an oral agent designed to treat glioblastoma multiforme by targeting iron-dependent metabolic pathways in cancer cells. IQ-AI's dual approach combines sophisticated diagnostic AI tools with targeted therapeutics to enhance patient outcomes in complex cancer cases.